A
Armando Santoro
Researcher at Humanitas University
Publications - 961
Citations - 56759
Armando Santoro is an academic researcher from Humanitas University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 93, co-authored 847 publications receiving 48505 citations. Previous affiliations of Armando Santoro include Aix-Marseille University & University of Milan.
Papers
More filters
Journal ArticleDOI
Clinical Review on the Management of Breast Cancer Visceral Crisis
C. Benvenuti,Mariangela Gaudio,F. Jacobs,Giuseppe Saltalamacchia,Rita De Sanctis,Rosalba Torrisi,Armando Santoro,Alberto Zambelli +7 more
TL;DR: In this article , the authors discuss the management of visceral crisis, advocating future treatment perspectives for this challenging condition, which is a life-threatening clinical condition requiring urgent treatment and accounts for 10-15% of new advanced breast cancer diagnoses, mainly hormone receptor positive/human epidermal growth factor 2 negative.
P27: humoral response rate post mrna covid19 vaccination (bnt162b2) is higly dependent to bone marrow plasmacytosis: long follow-up of symptomatic multiple myeloma patients
Giuseppe Mele,Catello Romano,Alessandro Spina,Francesca Merchionne,Giovanni Quintana,M Urbano,AM Pasanisi,Erminia Rinaldi,MP Solfrizzi,A. Romano,Gianluca Guaragna,ML DiNoi,Ageo Miccoli,Armando Santoro,Desa Rae Pastore +14 more
TL;DR: The myeloma treatment, including high-dose melphalan and autologous stem cell transplantation, have not been associated with SARS-CoV-2 infection and a significant fraction of MM patients does not developed any detectable anti-Spike IgG after two dose of COVID-19 mRNA vaccine.
Journal ArticleDOI
Selected memory T cells infused post haploidentical hematopoietic stem cell transplantation persist and hyper-expand.
Jasper J. P. van Beek,Simone Puccio,Clara Di Vito,Federica De Paoli,Elisa Zaghi,Michela Calvi,Alice Scarpa,Clelia Peano,Gianluca Basso,Javier Cibella,Chiara De Philippis,Barbara Sarina,I Timofeeva,R. Capizzuto,Daniele Mannina,Rossana Mineri,Jacopo Mariotti,Roberto Crocchiolo,Armando Santoro,Luca Castagna,Stefania Bramanti,Domenico Mavilio,Enrico Lugli +22 more
TL;DR: In this paper , a longitudinal analysis of the lymphocyte compartment in 19 haplo-HSCT patients previously enrolled in a phase II prospective clinical trial (ClinicalTrials.gov Identifier: NCT04687982), in which they received post-transplant CD45RA-depleted donor lymphocyte infusions (DLI), was performed.
Posted ContentDOI
Clinical, pathological and molecular predictors of Fulvestrant long-term benefit in Hormone Receptor-positive / HER2 negative advanced breast cancer
Rosalba Torrisi,Valentina Vaira,Laura Giordano,Annarita Destro,Vera Basilico,Saveria Mazzara,Piermario Salvini,Gabriella Gaudioso,Bethania Fernandes,Noemi Rudini,Giovanna Masci,Armando Santoro +11 more
TL;DR: The clinical findings are consistent with literature data, while the mutation and miRNA results provide some clues on the molecular mechanisms involved in fulvestrant activity and resistance to be confirmed in larger cohorts of breast cancer patients.
Journal ArticleDOI
PET-Driven Radiotherapy (RT) in Patients with Low Risk Diffuse Large B-Cell Lymphoma (DLBCL): 5-Year Results of the DLCL10 Multicenter Phase 2 Trial By Fondazione Italiana Linfomi (FIL)
Monica Balzarotti,Umberto Ricardi,Michele Spina,Andrea Evangelista,Alessandra Tucci,Federica Cavallo,Manuela Zanni,Annalisa Arcari,Vittorio Ruggero Zilioli,Roberto Sartori,Francesco Merli,Francesca Re,Umberto Vitolo,Maria Assunta Deidda,Luca Melis,D Dessi,Marcello Rodari,Armando Santoro,Gianluca Gaidano,Giovannino Ciccone,Stephane Chauvie,Maria Giuseppina Cabras +21 more
TL;DR: In this article , the role of residual uptake area (RUA) on PET negative sites after rituximab-chemotherapy (R-CT) was investigated in DLBCL patients.